CORDIS · 115861 · H2020
EBOVAC2 Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861
Coordinator: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR)
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.This will be done by:1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4)2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II stu…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
Co-funding: the European Union contributes €22.8M toward a total project budget of €50.7M — a funding rate of 45%, with the remainder covered by the consortium partners. The project runs over approximately 6.5 years from 2014-12-01 to 2021-05-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from FR
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FP7 · €250.0M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · HORIZON · €200.0M
- Biodiversa-plus — The European Biodiversity Partnership101052342 · HORIZON · €105.0M
- OFELIA — Open Fan for Environmental Low Impact of Aviation101102011 · HORIZON · €100.0M
- EPI SGA1 — SGA1 (Specific Grant Agreement 1) OF THE EUROPEAN PROCESSOR INITIATIVE (EPI)826647 · H2020 · €80.0M
- Water4All — Water4All – Water Security for the Planet101060874 · HORIZON · €56.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the IMI2-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €22.8M toward a total project budget of €50.7M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2014-02-single-stage.
- Who coordinates the project?
- The project is coordinated by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR).
- What is the project timeline?
- The project runs from 2014-12-01 to 2021-05-31 — approximately 6.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115861.